These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29484450)

  • 1. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
    Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
    Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
    Kotaka M; Yoshino T; Oba K; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Goto K; Sakamoto J; Saji S; Ohtsu A; Watanabe T
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):75-84. PubMed ID: 25983021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
    J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
    Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
    Danno K; Hata T; Tamai K; Fujie Y; Ide Y; Kim HM; Ohnishi T; Morita S; Yoshioka S; Kudo T; Nishimura J; Matsuda C; Akamatsu H; Mizushima T; Nezu R; Doki Y; Mori M; ;
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):777-785. PubMed ID: 28825216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
    Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
    Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
    Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
    Chang W; Wei Y; Ren L; Zhong Y; Yu Y; Chen J; Zhu D; Ye L; Qin C; Zhao N; Niu W; Qin X; Xu J
    Ann Surg; 2016 Mar; 263(3):434-9. PubMed ID: 26465781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
    Xie Q; Wen F; Wei YQ; Deng HX; Li Q
    Colorectal Dis; 2013 Aug; 15(8):958-62. PubMed ID: 23506229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
    BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
    Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
    Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
    Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
    J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
    Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Kawada J; Takagi M; Fukui A; Iwase K; Tanaka Y
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):743-7. PubMed ID: 25129086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
    Lu GC; Fang F; Li DC
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.